Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS II in untreated mantle cell lymphoma
2024-512634-15-00Phase 2Authorised
- Sponsor
- LYSARC
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of ibrutinib, venetoclax, rituximab and obinutuzumab in mantle cell lymphoma (MCL) (2 arms), sponsored by LYSARC. Primary endpoint: MRD negativity rate at end of induction. Planned start May 2024; status: authorised.
02
Drugs
ibrutinibvenetoclaxrituximabobinutuzumab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2024-512634-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512634-15-00.